NCT06178601View on ClinicalTrials.gov

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

April 1, 2026

Conditions
Urothelial Carcinoma
Interventions
DRUG

RC48-ADC

RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）

DRUG

AK104

AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC

Trial Locations (2)

100000

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

030000

RECRUITING

Shanxi Province Cancer Hospital, Taiyuan

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Shanxi Province Cancer Hospital

OTHER